ATR 1072 in Participants With PRKAG2 Syndrome

计划入组 37 人 · 首次发布于 2026 年 7 月 31 日

First-in-human Single and Multiple Dose Trial of ATR-258

计划入组 71 人 · 首次发布于 2022 年 6 月 8 日

Endometriosis and ATR-FTIR Spectroscopy

计划入组 600 人 · 首次发布于 2024 年 5 月 23 日

ATR-107

ATR-120

ATR-04

Astron Corp Ltd

United States

Cardinal Health 107, LLC

United States

ATSR LIMITED

Ireland

Atrium Therapeutics Secures FDA Clearance of IND for ATR-1072, First Disease-Modifying Therapy for PRKAG2 Syndrome

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb for Second Lead Compound in Cardiovascular RNA Collaboration

CytoSorbents' DrugSorb-ATR Receives FDA Priority Review for Bleeding Reduction in Heart Surgery